Of note, FAK has been found activated or up-regulated in several pediatric cancers, such as renal cancer, neuroblastoma, ewing sarcoma, rhabdomyosarcoma and hepatocellular carcinoma, and FAK depletion or pharmacologic inhibition has resulted in tumor growth impairment, both in vitro and in vivo [4,9,22,32,101,102,103,104,105]. This evidence concerns the gene PTK2 and neoplasm.